120 related articles for article (PubMed ID: 23210825)
1. Global update: USA.
Matthews KR; Rowland ML
Regen Med; 2012 Nov; 7(6 Suppl):126-9. PubMed ID: 23210825
[TBL] [Abstract][Full Text] [Related]
2. Global update: USA.
Matthews KR
Regen Med; 2011 Nov; 6(6 Suppl):136-9. PubMed ID: 21999276
[TBL] [Abstract][Full Text] [Related]
3. State stem cell agency floats idea of $70 million 'Alpha' clinics.
Dolgin E
Nat Med; 2013 Jul; 19(7):798. PubMed ID: 23836206
[No Abstract] [Full Text] [Related]
4. Global update: Canada.
Willemse L; Ogbogu U; Johnson S; Rudnicki M
Regen Med; 2012 Nov; 7(6 Suppl):132-5. PubMed ID: 23210826
[TBL] [Abstract][Full Text] [Related]
5. Local and global returns from research in stem cells: the case of the California Institute for Regenerative Medicine.
Alberro J
Regen Med; 2012 Jul; 7(4):605-13. PubMed ID: 22817632
[TBL] [Abstract][Full Text] [Related]
6. Global update: Brazil.
Mendez-Otero R; Campos de Carvalho AC
Regen Med; 2012 Nov; 7(6 Suppl):144-7. PubMed ID: 23210829
[TBL] [Abstract][Full Text] [Related]
7. Global update: Sweden.
Hovatta O
Regen Med; 2012 Nov; 7(6 Suppl):140-2. PubMed ID: 23210828
[TBL] [Abstract][Full Text] [Related]
8. A new paradigm for funding medical research.
Klein R
Stem Cells; 2012 Mar; 30(3):360-2. PubMed ID: 22334458
[No Abstract] [Full Text] [Related]
9. Why regenerative stem cell medicine progresses slower than expected.
Rosemann A
J Cell Biochem; 2014 Dec; 115(12):2073-6. PubMed ID: 25079695
[No Abstract] [Full Text] [Related]
10. The need for a regen industry voice.
Mason C; Dunnill P
Regen Med; 2008 Sep; 3(5):621-31. PubMed ID: 18729785
[No Abstract] [Full Text] [Related]
11. Global update: UK.
Culme-Seymour EJ
Regen Med; 2012 Nov; 7(6 Suppl):136-8. PubMed ID: 23210827
[TBL] [Abstract][Full Text] [Related]
12. The international translational regenerative medicine center.
Alexis Mde V; Grinnemo KH; Jove R
Regen Med; 2012 Nov; 7(6 Suppl):74-5. PubMed ID: 23210815
[TBL] [Abstract][Full Text] [Related]
13. The NIH and the regenerative medicine field.
Rao M
Regen Med; 2012 Mar; 7(2):129-31. PubMed ID: 22397601
[No Abstract] [Full Text] [Related]
14. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics.
Lysaght MJ; Jaklenec A; Deweerd E
Tissue Eng Part A; 2008 Feb; 14(2):305-15. PubMed ID: 18333783
[TBL] [Abstract][Full Text] [Related]
15. Stem cell-based therapies: promises, obstacles, discordance, and the agora.
Eggleson KK
Perspect Biol Med; 2012; 55(1):1-25. PubMed ID: 22643713
[TBL] [Abstract][Full Text] [Related]
16. The continued promise of stem cell therapy in regenerative medicine.
Eve DJ
Med Sci Monit; 2011 Dec; 17(12):RA292-305. PubMed ID: 22179483
[TBL] [Abstract][Full Text] [Related]
17. Global update: Germany.
Lauter FR; Wirsching S
Regen Med; 2011 Nov; 6(6 Suppl):154-7. PubMed ID: 21999280
[TBL] [Abstract][Full Text] [Related]
18. [The industrialization of regenerative medicine--a potential market of $ 500 billion].
Gu Q; Zhang X; Jiang L
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Sep; 21(9):1011-5. PubMed ID: 17933243
[TBL] [Abstract][Full Text] [Related]
19. Stem cell industry update: 2012 to 2016 reveals accelerated investment, but market capitalization and earnings lag.
Ng M; Song S; Piuzzi NS; Ng K; Gwam C; Mont MA; Muschler GF
Cytotherapy; 2017 Oct; 19(10):1131-1139. PubMed ID: 28807603
[TBL] [Abstract][Full Text] [Related]
20. 2010 World Stem Cell Summit--part 1. October 4-6, 2010, Detroit, MI, USA.
Vertès A
IDrugs; 2010 Dec; 13(12):819-21. PubMed ID: 21154132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
